Trial Profile

A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MEDI0382 in Overweight/Obese Subjects With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cotadutide (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors AstraZeneca; MedImmune

Most Recent Events

16 Jun 2020 Results assessing the safety and efficacy of cotadutide in doses up to 600 µg in patients with T2DM, were presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
10 Jun 2019 Status changed from active, no longer recruiting to completed.
20 Feb 2019 Planned End Date changed from 10 Jun 2019 to 6 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com